This chapter about the recognition, treatment, and prevention of heparin-induced
thrombocytopenia (HIT) is part of the Antithrombotic and Thrombolytic Therapy: American …

This chapter about the recognition, treatment, and prevention of heparin-induced
thrombocytopenia (HIT) is part of the Seventh ACCP Conference on Antithrombotic and …

Background Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse
drug reaction that can lead to devastating thromboembolic complications, including …

Heparin-induced thrombocytopenia (HIT) is one of the most important life-and limb-
threatening adverse drug events encountered by physicians. Serious sequelae associated …

Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy that
has a high rate of morbidity (thrombosis and amputation) and mortality. In the past, a number …

For patients with heparin-induced thrombocytopenia (HIT), reexposure to heparin is
generally not recommended. However, these patients are likely to require anticoagulation …

Heparin-induced thrombocytopenia (HIT) is an uncommon but potentially devastating
complication of anticoagulation with unfractionated heparin (UFH) or low-molecular-weight …

Immune heparin-induced thrombocytopenia (HIT) is a relevant adverse drug reaction
consisting in a hypercoagulable state caused by an anticoagulant agent. The incidence is …

Heparin-induced thrombocytopenia (HIT) is an immunoglobulin-mediated adverse drug
reaction associated with a high risk of thrombotic complications. The pathogenic antibody …

The purpose of this study is to determine the incidence of heparin-associated
thrombocytopenia (HAT) for various subgroups of heparin exposed patients and the impact …